Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ModraDoc006/r in Liver Impaired Patients
NCT05084456Phase 1Withdrawn
- Sponsor
- Modra Pharmaceuticals
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ModraDoc006 in solid tumor (3 arms), sponsored by Modra Pharmaceuticals. Primary endpoints: Area Under the Curve of Docetaxel and Hematological and Non-hematological Toxicity Profile. Planned start Jul 2017; status: withdrawn.
02
Drugs
ModraDoc006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05084456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084456.